Clinical Trials Browser

NCT01681433 2022-07-11

OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone

Phase 2 Terminated

72 enrolled 14 charts

Genitourinary

Prostatic Neoplasms

NCT01780545 2022-07-11

Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer

Phase 2 Completed

200 enrolled 11 charts

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT01120470 2019-02-15

OGX-427 in Castration Resistant Prostate Cancer Patients

Phase 2 Completed

74 enrolled

Genitourinary

Prostatic Neoplasms

NCT01829113 2018-06-08

Spruce

Phase 2 Completed

155 enrolled 12 charts

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02423590 2017-08-22

Study of Gemcitabine/Carboplatin First-line Chemotherapy +/- Apatorsen in Advanced Squamous Cell Lung Cancers

Phase 2 Unknown

140 enrolled

Thoracic

Squamous Cell Lung Cancer

NCT01844817 2017-05-16

Rainier

Phase 2 Completed

132 enrolled 9 charts

Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

NCT01454089 2016-10-07

A Phase 2 Study Comparing Chemotherapy in Combination With OGX-427 or Placebo in Patients With Bladder Cancer

Phase 2 Completed

183 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT00487786 2016-01-18

Safety Study of an Antisense Product in Prostate, Ovarian, NSCL, Breast or Bladder Cancer

Phase 1 Completed

64 enrolled

Tumor-Agnostic

Neoplasms

NCT00959868 2012-02-13

A Study for Treatment of Superficial Bladder Cancer Using OGX-427

Phase 1 Unknown

36 enrolled

Genitourinary

Neuronopathy, Distal Hereditary Motor, Type IIB, Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms